Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microdosed Semaglutide for Health and Longevity
NCT07092605Phase 1Enrolling by invitation
- Sponsor
- AgelessRx
- Start
- Nov 2024
- Primary completion
- Nov 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of semaglutide in aging (3 arms), sponsored by AgelessRx. Primary endpoints: Change in self-reported pain levels at 6 months, Concentration of complete blood cells at 6 months and 5 more. Started Nov 2024; status: enrolling by invitation.
02
Drugs
03
Conditions
aging
Beyond the preview
Go deeper on NCT07092605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07092605.